Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Importation Proposal: Rigorous Requirements May Limit Impact

Executive Summary

Proposed rule allowing states to import certain drugs from Canada would require tight supply chain, extensive security and reporting responsibilities. The potential costs and rigor involved in implementing the program could impede its uptake. 

You may also be interested in...



Presidential Arm Twisting: Drug Pricing Order Would Advance International Benchmarks Unless Industry Offers Alternative

Industry has 30 days to come up with a better idea that would “end foreign free riding” and close the gap between drug prices in the US and abroad, President Trump says. Administration also wants to revive rebate reform.

Presidential Arm Twisting: Drug Pricing Order Would Advance International Benchmarks Unless Industry Offers Alternative

Industry has 30 days to come up with a better idea that would “end foreign free riding” and close the gap between drug prices in the US and abroad, President Trump says. Administration also wants to revive rebate reform.

Pharma Outpaces All Other Industries In US Federal Lobbying Spending

Over the past 20 years, the pharmaceutical industry has notched a series of wins with its extraordinary federal lobbying expenditures and campaign contributions. A new JAMA Internal Medicine study examines spending from 1999-2018.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel